← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Virrx, Inc
Chesterfield, MO
$2,096,463
Total funding
8
Grants
Funding over time
peak $260.9K · FY2007–09$500K$375K$250K$125K$0
'07
'08
'09
Funding mix
By agency
NIH$2,096,463 · 8
By mechanism
R41$736,159 · 4
R42$711,039 · 1
R43$649,265 · 3
Investigators at Virrx, Inc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Adenovirus Replication-Competent Anti-Cancer Vector$359,756
R42 · FY2003 · CA
Adenovirus Replication-Competent Anti-Cancer Vector$351,283
R42 · FY2002 · CA
An HBV polymerase RNA binding assay suitable for inhibitor screening$260,910
R43 · FY2009 · AI
Anti-Cancer Vectors that Express TRAIL$247,645
R43 · FY2004 · CA
Syrian Hamster as a Permissive Model for Testing Anti-Adenovirus Drugs$222,658
R41 · FY2007 · AI
Animal Model for Adenovirus Oncolytic Vectors$182,459
R41 · FY2004 · CA
Chaperone-based tumor therapy delivered by viral vectors$169,167
R41 · FY2003 · CA
Regulatable expression of TRAIL and viral oncolysis$161,875
R41 · FY2004 · CA
Development of a virus vector vaccine against anthrax$140,710
R43 · FY2002 · AI